JP2022552262A5 - - Google Patents
Info
- Publication number
- JP2022552262A5 JP2022552262A5 JP2022521243A JP2022521243A JP2022552262A5 JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5 JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- months
- mmol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911968P | 2019-10-07 | 2019-10-07 | |
| US62/911,968 | 2019-10-07 | ||
| PCT/US2020/054400 WO2021071835A1 (en) | 2019-10-07 | 2020-10-06 | Adeno-associated virus vector pharmaceutical composition and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552262A JP2022552262A (ja) | 2022-12-15 |
| JP2022552262A5 true JP2022552262A5 (https=) | 2023-10-17 |
Family
ID=73131798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521243A Pending JP2022552262A (ja) | 2019-10-07 | 2020-10-06 | アデノ随伴ウイルスベクター医薬組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240108669A1 (https=) |
| EP (1) | EP4041292A1 (https=) |
| JP (1) | JP2022552262A (https=) |
| KR (1) | KR20220081365A (https=) |
| CN (1) | CN114728049A (https=) |
| AR (1) | AR120171A1 (https=) |
| AU (1) | AU2020362119A1 (https=) |
| BR (1) | BR112022006718A2 (https=) |
| CA (1) | CA3156984A1 (https=) |
| IL (1) | IL291930A (https=) |
| MX (1) | MX2022004146A (https=) |
| TW (2) | TWI879814B (https=) |
| WO (1) | WO2021071835A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| US20240066146A1 (en) * | 2020-12-18 | 2024-02-29 | Sangamo Therapeutics, Inc. | Improved pharmaceutical compositions containing adeno-associated viral vector |
| WO2023177626A1 (en) * | 2022-03-14 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Lyophilized formulations of aav drug products |
| TW202404651A (zh) * | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
| WO2024138129A2 (en) * | 2022-12-23 | 2024-06-27 | Spark Therapeutics, Inc. | Adeno-associated virus formulations |
| WO2024220966A1 (en) * | 2023-04-21 | 2024-10-24 | The Regents Of The University Of California | Novel glycan compounds for age-related macular degeneration |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| TW202508610A (zh) * | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025045083A1 (zh) * | 2023-09-01 | 2025-03-06 | 康霖生物科技（杭州）有限公司 | 一种液体制剂及其用途 |
| CN119769462A (zh) * | 2023-10-07 | 2025-04-08 | 陈国韬 | 一种非器质性（心理性）勃起功能障碍大鼠模型的构建方法 |
| WO2025113676A1 (en) * | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| TW202548025A (zh) | 2024-04-08 | 2025-12-16 | 美商銳進科斯生物股份有限公司 | 載體化抗補體抗體與補體劑及其投與 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| AU719001B2 (en) | 1994-12-29 | 2000-05-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| JP2001514007A (ja) | 1997-08-27 | 2001-09-11 | アリアド ジーン セラピューティクス インコーポレイテッド | キメラ転写アクチベーター、ならびにそれに関連する組成物および使用 |
| JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| KR20240005973A (ko) | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| KR20190038536A (ko) * | 2016-06-16 | 2019-04-08 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 안구 혈관신생을 저하시키기 위한 조성물 및 방법 |
| BR112019009113A2 (pt) * | 2016-11-04 | 2019-07-16 | Baxalta Incorporated | formulações de vírus adenoassociado |
| EP3808849A1 (en) * | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| EP3687464A4 (en) | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB |
| BR112021009370A2 (pt) * | 2018-11-14 | 2021-08-17 | Regenxbio Inc. | método de tratamento da doença de batten cln2, composição farmacêutica e kit |
-
2020
- 2020-10-06 WO PCT/US2020/054400 patent/WO2021071835A1/en not_active Ceased
- 2020-10-06 EP EP20801425.8A patent/EP4041292A1/en active Pending
- 2020-10-06 KR KR1020227015158A patent/KR20220081365A/ko active Pending
- 2020-10-06 CA CA3156984A patent/CA3156984A1/en active Pending
- 2020-10-06 CN CN202080079668.3A patent/CN114728049A/zh active Pending
- 2020-10-06 BR BR112022006718A patent/BR112022006718A2/pt unknown
- 2020-10-06 US US17/766,941 patent/US20240108669A1/en active Pending
- 2020-10-06 JP JP2022521243A patent/JP2022552262A/ja active Pending
- 2020-10-06 AU AU2020362119A patent/AU2020362119A1/en active Pending
- 2020-10-06 IL IL291930A patent/IL291930A/en unknown
- 2020-10-06 MX MX2022004146A patent/MX2022004146A/es unknown
- 2020-10-07 AR ARP200102778A patent/AR120171A1/es unknown
- 2020-10-07 TW TW109134835A patent/TWI879814B/zh active
- 2020-10-07 TW TW114110012A patent/TW202525312A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022552262A5 (https=) | ||
| US7740842B2 (en) | Stable liquid formulations of antibodies | |
| JP2024178197A (ja) | 液体医薬組成物 | |
| AU2013255413C1 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| CN102946861B (zh) | 浓缩蛋白制剂及其用途 | |
| TWI725973B (zh) | 抗-ｃｇｒｐ抗體調配物 | |
| CN1293916C (zh) | 稳定的胰岛素制剂 | |
| JP2022153418A5 (https=) | ||
| JP2024016207A5 (https=) | ||
| JP2021516671A5 (https=) | ||
| JP2021504372A5 (https=) | ||
| JP7089121B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| RU2664691C2 (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| JP2022545967A5 (https=) | ||
| WO2019020777A1 (en) | LIQUID FORMULATION OF A VEGF ANTAGONIST | |
| CN116056688A (zh) | 眼用液体组合物 | |
| JP6852049B2 (ja) | 改善された安定性を有するエタネルセプト組成物 | |
| WO2025177156A1 (en) | Stable ophthalmic pharmaceutical formulation of aflibercept | |
| AU2006202688B2 (en) | Stable liquid formulations of antibodies | |
| AU2002321055A1 (en) | Stable liquid formulations of antibodies | |
| HK1223835B (zh) | 浓缩蛋白制剂及其用途 | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| HK1207316B (zh) | 抗催乳素受体抗体制剂 |